Quick Summary:
The global renal biomarkers industry is witnessing significant growth, propelled by the ever-growing cases of kidney diseases worldwide. Renal biomarkers, spanning from cells, proteins, lipids, microRNAs, genes, to metabolites, play an essential role in diagnosing and monitoring chronic kidney disease (CKD). These biomarkers not only aid in assessing kidney's proper functioning but also help in predicting disease progression and adjusting respective drug dosage.
In addition, the rise of interest among industry investors in innovative biomarkers, including blood urea nitrogen (BUN), serum creatinine (SCr), urinary albumin/protein, and volume excretion, uniquely positions this market for strong growth. The sector's development and integration of genomics, epigenetics, transcriptomics, proteomics, and metabolomics have also notably influenced the market. With renal biomarkers becoming increasingly accessible in laboratories of all sizes, and healthcare advancements catalyzing further innovations, investment in the renal biomarkers market may hold substantial potential for business leaders in the medical field.
The global renal biomarkers market size reached US$ 1.2 Billion in 2022. Looking forward, the publisher expects the market to reach US$ 2.0 Billion by 2028, exhibiting a growth rate (CAGR) of 7.8% during 2023-2028.
Renal biomarkers are cells, proteins, lipids, microRNAs, genes, metabolites, or proteomic patterns present on a urinalysis. They assist in determining the glomerular filtration rate (GFR) of kidneys to analyze their proper functioning and evaluating pathogenic processes or pharmacological responses to therapeutic interventions. As they also aid in predicting disease progression and computing drug dosage, renal biomarkers find extensive applications in hospitals and diagnostic laboratories across the globe.
2. What is the expected growth rate of the global renal biomarkers market during 2023-2028?
3. What has been the impact of COVID-19 on the global renal biomarkers market?
4. What are the key factors driving the global renal biomarkers market?
5. What is the breakup of the global renal biomarkers market based on the biomarker type?
6. What is the breakup of the global renal biomarkers market based on the diagnostic technique?
7. What is the breakup of the global renal biomarkers market based on end user?
8. What are the key regions in the global renal biomarkers market?
9. Who are the key players/companies in the global renal biomarkers market?
Renal biomarkers are cells, proteins, lipids, microRNAs, genes, metabolites, or proteomic patterns present on a urinalysis. They assist in determining the glomerular filtration rate (GFR) of kidneys to analyze their proper functioning and evaluating pathogenic processes or pharmacological responses to therapeutic interventions. As they also aid in predicting disease progression and computing drug dosage, renal biomarkers find extensive applications in hospitals and diagnostic laboratories across the globe.
Renal Biomarkers Market Trends:
Chronic kidney disease (CKD), non-communicable disease with considerable morbidity and mortality, has gradually become a public health concern globally and its main risk factors are diabetes, hypertension and heart diseases. The increasing number of individuals with CKD represents one of the key factors propelling the growth of the market. Moreover, renal biomarkers, including blood urea nitrogen (BUN), serum creatinine (SCr), urinary albumin/protein and volume excretion, are used in the diagnosis of chronic kidney disease (CKD) and monitoring of the disease. Besides this, there is a growing interest of industry investors in novel single biomarkers and process-specific biomarker panels in human renal diseases around the world. These novel biomarkers provide vital diagnostic and prognostic information and help predict response to the treatment of glomerulopathies, acute kidney injury (AKI), and autosomal dominant polycystic kidney disease (ADPKD). Apart from this, renal biomarkers are becoming accessible and feasible in all-sized laboratories. This, along with the development and integration of genomics, epigenetics, transcriptomics, proteomics, and metabolomics, is positively influencing the market. Some of the other factors, such as the burgeoning healthcare industry, the rising geriatric population, and the increasing number of clinical trials for CKD worldwide, are anticipated to facilitate the growth of the market.Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global renal biomarkers market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on biomarker type, diagnostic technique and end user.Breakup by Biomarker Type:
- Functional Biomarker
- Serum Creatinine
- Serum Cystatin C
- Urine Albumin
- Up-regulated Protein
- Neutrophil Gelatinase-Associated Lipocalin (NGAL)
- Kidney Injury Molecule-1
- INTERLEUKIN-18
- Others
Breakup by Diagnostic Technique:
- Enzyme-linked Immunosorbent Assay (ELISA)
- Particle-enhanced Turbidimetric Immunoassay (PETIA)
- Colorimetric Assay
- Chemiluminescent Enzyme Immunoassay (CLIA)
- Liquid Chromatography Mass Spectrometry (LC-MS)
Breakup by End User:
- Hospital
- Diagnostic Laboratory
- Others
Breakup by Region:
North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Beckman Coulter Inc. (Danaher Corporation), bioMérieux SA, BioPorto A/S, Bio-Rad Laboratories Inc., Enzo Biochem Inc., F. Hoffmann-La Roche AG, PerkinElmer Inc., Randox Laboratories Ltd., Siemens AG and Thermo Fisher Scientific Inc.Key Questions Answered in This Report
1. What was the size of the global renal biomarkers market in 2022?2. What is the expected growth rate of the global renal biomarkers market during 2023-2028?
3. What has been the impact of COVID-19 on the global renal biomarkers market?
4. What are the key factors driving the global renal biomarkers market?
5. What is the breakup of the global renal biomarkers market based on the biomarker type?
6. What is the breakup of the global renal biomarkers market based on the diagnostic technique?
7. What is the breakup of the global renal biomarkers market based on end user?
8. What are the key regions in the global renal biomarkers market?
9. Who are the key players/companies in the global renal biomarkers market?
Frequently Asked Questions about the Global Renal Biomarkers Market
What is the estimated value of the Global Renal Biomarkers Market?
What is the growth rate of the Global Renal Biomarkers Market?
What is the forecasted size of the Global Renal Biomarkers Market?
Who are the key companies in the Global Renal Biomarkers Market?
| Report Attribute | Details |
|---|---|
| No. of Pages | 144 |
| Published | May 2023 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 1.2 Billion |
| Forecasted Market Value ( USD | $ 2 Billion |
| Compound Annual Growth Rate | 8.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
Table of Contents
1 Preface3 Executive Summary11 Value Chain Analysis13 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Renal Biomarkers Market
6 Market Breakup by Biomarker Type
7 Market Breakup by Diagnostic Technique
8 Market Breakup by End User
9 Market Breakup by Region
10 SWOT Analysis
12 Porters Five Forces Analysis
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Abbott Laboratories
- Beckman Coulter Inc. (Danaher Corporation)
- bioMérieux SA
- BioPorto A/S
- Bio-Rad Laboratories Inc.
- Enzo Biochem Inc.
- F. Hoffmann-La Roche AG
- PerkinElmer Inc.
- Randox Laboratories Ltd.
- Siemens AG
- Thermo Fisher Scientific Inc.
Methodology
LOADING...
